Same name, different dollars

After nearly 25 years, Frazier Healthcare is separating its life sciences venture investments from its growth buyouts. Both groups will still operate under the Frazier name, but the new $262 million Frazier Life Sciences VIII fund will have only two managing general partners calling the shots.

Within life sciences, the firm isn't changing its strategy of investing in therapeutics. Frazier expects to make a total of about 15 investments from the new fund, which closed last week...